Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis

Clinical and Experimental Immunology

Volumn 187, Issue 3, 2017, Pages 376-382

  Phatak, S ^a   Chaurasia, S ^a   Mishra, S K ^a   Gupta, R ^a   Agrawal, V ^a   Aggarwal, A ^a   Misra, R ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

B cell; cytokines; systemic lupus erythematosus

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; TNFSF13 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REMISSION; SLEDAI; TREATMENT RESPONSE; B LYMPHOCYTE; DRUG EFFECTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; URINE; YOUNG ADULT;

ADULT; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 85006390505     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12894     Document Type: Article

References (37)

1. Misra R, Gupta R. Biomarkers in lupus nephritis. Int J Rheum Dis 2015; 18:219–32.
2. Gupta R, Yadav A, Aggarwal A. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity. Clin Rheumatol 2016; 35:2707–14.
3. Gupta R, Yadav A, Misra R, Aggarwal A. Urinary sCD25 as a biomarker of lupus nephritis disease activity. Lupus 2014; 24:273–9.
4. Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58:2453–9.
5. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 2010; 135:118–24.
6. Stohl W, Metyas S, Tan SM et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63:1096–103.
7. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48:3475–86.
8. Collins CE, Gavin AL, Migone T-S, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2005; 8:R6.
9. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363–9.
10. Boumpas D, Balow J. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7:622–9.
11. Liang MH, Schur PH, Fortin P et al. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54:421–32.
12. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121–31.
13. Boumpas D, Austin HA, Balow J et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741–5.
14. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198:937–45.
15. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10:365–73.
16. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp Med 1999; 190:1697–710.
17. Zhao L, Li Y, Smith M et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010; 19:1534–49.
18. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721–31.
19. Petri MA, Vollenhoven RF, Buyon J et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013; 65:2143–53.
20. Parodis I, Zickert A, Sundelin B et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med 2015; 2:e000061.
21. Vincent F, Northcott M, Hoi A, Mackay F, Morand E. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22:873–84.
22. Golder V, Connelly K, Staples M, Morand E, Hoi A. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 2013: 22:1425–30.
23. Vallerskog T, Heimburger M, Gunnarsson I et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R167.
24. Stein JV, López-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109:1587–98.
25. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9:491–502.
26. Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1065–7.
27. Morel J, Roubille C, Planelles L et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68:997–1002.
28. Treamtrakanpon W, Tantivitayakul P, Benjachat T et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther 2012; 14:R252.
29. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112:286–97.
30. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic Iupus erythematosus: Relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10:R97.
31. Neusser MA, Lindenmeyer MT, Edenhofer I et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 2011; 24:98–107.
32. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune–based rheumatic diseases. Arthritis Rheum 2001; 44:1313–9.
33. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639–48.
34. Boucher A, Droz D, Adafer E, Noël L-H. Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. Kidney Int 1986; 29:1043–9.
35. Chang A, Henderson SG, Brandt D et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011; 186:1849–60.
36. Shen Y, Sun C-Y, Wu F-X et al. Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases. Clin Dev Immunol 2012; 2012:967584.
37. Kopetschke K, Klocke J, Grießbach A-S et al. The cellular signature of urinary immune cells in lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther 2015; 17:1.